Skip to main content

Articles

Page 5 of 64

  1. Tyrosine kinase inhibitors (TKIs) alone and in combination with immune checkpoint inhibitors (ICIs) have been shown to be beneficial for the survival of metastatic renal cell carcinoma (mRCC) patients, but res...

    Authors: Wentao Liu, Dianyun Ren, Wei Xiong, Xin Jin and Liang Zhu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:38
  2. Lung adenocarcinoma (LUAD)  is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD are far from satisfactory. Recently, targeting N6-methyladenos...

    Authors: Lifang Ma, Xiangfei Xue, Xiao Zhang, Keke Yu, Xin Xu, Xiaoting Tian, Yayou Miao, Fanyu Meng, Xiaoxin Liu, Susu Guo, Shiyu Qiu, Yikun Wang, Jiangtao Cui, Wanxin Guo, You Li, Jinjing Xia…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:36
  3. Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The current standard of care involves surgical resection (if possible) followed by concomitant radiotherapy and chemotherapy. ...

    Authors: Mathilde Bausart, Véronique Préat and Alessio Malfanti
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:35
  4. Acute myeloid leukemia (AML) is characterized by accumulation of aberrantly differentiated hematopoietic myeloid progenitor cells. The karyotyping-silent NUP98-NSD1 fusion is a molecular hallmark of pediatric ...

    Authors: Zivojin Jevtic, Vittoria Matafora, Francesca Casagrande, Fabio Santoro, Saverio Minucci, Massimilliano Garre’, Milad Rasouli, Olaf Heidenreich, Giovanna Musco, Jürg Schwaller and Angela Bachi
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:34
  5. Depletion of certain ribosomal proteins induces p53 activation, which is mediated mainly by ribosomal protein L5 (RPL5) and/or ribosomal protein L11 (RPL11). Therefore, RPL5 and RPL11 may link RPs and p53 acti...

    Authors: Hongyan Li, Hong Zhang, Guomin Huang, Zhitong Bing, Duling Xu, Jiadi Liu, Hongtao Luo and Xiaoli An
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:33
  6. tRNA-derived fragments (tRFs) have been shown to have critical regulatory roles in cancer biology. However, the contributions of tRFs to colorectal cancer (CRC) remain largely unknown.

    Authors: Ying Han, Yinghui Peng, Shanshan Liu, Xinwen Wang, Changjing Cai, Cao Guo, Yihong Chen, Le Gao, Qiaoqiao Huang, Min He, Edward Shen, Jie Long, Jian Yu, Hong Shen and Shan Zeng
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:32
  7. The role of the microbiota in human health and disease is well established, including its effects on several cancer types. However, the role of microbial dysbiosis in prostate cancer development, progression, ...

    Authors: Paul Vinu Salachan and Karina Dalsgaard Sørensen
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:31
  8. Authors: Hao Peng, Jian Zhang, Pan-Pan Zhang, Lei Chen, Ling-Long Tang, Xiao-Jing Yang, Qing-Mei He, Xin Wen, Ying Sun, Na Liu, Ying-Qin Li and Jun Ma
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:30

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:11

  9. Cancer stem cells (CSCs) are generated under irregular microenvironment in vivo, of which mimic is quite difficult due to the lack of enough information of the factors responsible for cancer initiation. Here, ...

    Authors: Ghmkin Hassan, Toshiaki Ohara, Said M. Afify, Kazuki Kumon, Maram H. Zahra, Xiaoying Fu, Mohamad Al Kadi, Akimasa Seno, David S. Salomon and Masaharu Seno
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:29
  10. Estrogen-related receptor α (ERRα) has been reported to play a critical role in endometrial cancer (EC) progression. However, the underlying mechanism of ERRα-mediated lipid reprogramming in EC remains elusive...

    Authors: Xiaodan Mao, Huifang Lei, Tianjin Yi, Pingping Su, Shuting Tang, Yao Tong, Binhua Dong, Guanyu Ruan, Alexander Mustea, Jalid Sehouli and Pengming Sun
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:28
  11. The RAS oncogene is both the most frequently mutated oncogene in human cancer and the first confirmed human oncogene to be discovered in 1982. After decades of research, in 2013, the Shokat lab achieved a seminal...

    Authors: Albert K. Kwan, Gary A. Piazza, Adam B. Keeton and Caio A. Leite
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:27
  12. Recently, a hotspot mutation in prolactinoma was observed in splicing factor 3b subunit 1 (SF3B1R625H), but its functional effects and underlying molecular mechanisms remain largely unexplored.

    Authors: Jing Guo, Chuzhong Li, Qiuyue Fang, Yulou Liu, Dawei Wang, Yiyuan Chen, Weiyan Xie and Yazhuo Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:26
  13. Oncogenic KRAS mutations are prevalent in human cancers, but effective treatment of KRAS-mutant malignancies remains a major challenge in the clinic. Increasing evidence suggests that aberrant metabolism plays a ...

    Authors: Zhang Yang, Shun-Qing Liang, Liang Zhao, Haitang Yang, Thomas M. Marti, Balazs Hegedüs, Yanyun Gao, Bin Zheng, Chun Chen, Wenxiang Wang, Patrick Dorn, Gregor J. Kocher, Ralph A. Schmid and Ren-Wang Peng
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:25
  14. The development of lethal cancer metastasis depends on the dynamic interactions between cancer cells and the tumor microenvironment, both of which are embedded in the extracellular matrix (ECM). The acquisitio...

    Authors: Jingjing Zhang, Yun Li, Hua Liu, Jiahui Zhang, Jie Wang, Jia Xia, Yu Zhang, Xiang Yu, Jinyan Ma, Masha Huang, Jiahui Wang, Liangzhe Wang, Qian Li, Rutao Cui, Wen Yang, Yingjie Xu…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:24
  15. Recent data indicated that macrophages may mutually interact with cancer cells to promote tumor progression and chemoresistance, but the interaction in cholangiocarcinoma (CCA) is obscure.

    Authors: Tao Yang, Zhengdong Deng, Lei Xu, Xiangyu Li, Tan Yang, Yawei Qian, Yun Lu, Li Tian, Wei Yao and Jianming Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:23
  16. Epithelial-mesenchymal transition (EMT) has been associated with the angiogenesis and oncogenic phenotypes of multiple malignant tumors including bladder cancer (BCa). Circular RNAs (circRNAs) are recognized a...

    Authors: Feng Qiu, Qiuchen Liu, Yanfu Xia, Hengxi Jin, Yuxin Lin and Xiaojun Zhao
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:22
  17. Follicular lymphoma (FL) is a B-cell non-Hodgkin lymphoma of germinal center (GC) origin with a distinctive tumor microenvironment (TME) and a unique spectrum of mutations. Despite the important therapeutic ad...

    Authors: Rada Amin and Mounia S. Braza
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:21
  18. The long non-coding RNA (lncRNA), MALAT1, plays a key role in the development of different cancers, and its expression is associated with worse prognosis in patients. However, its mechanism of action and its r...

    Authors: Carmela Ferri, Anna Di Biase, Marco Bocchetti, Silvia Zappavigna, Sarah Wagner, Pauline Le Vu, Amalia Luce, Alessia Maria Cossu, Jayakumar Vadakekolathu, Amanda Miles, David J. Boocock, Alex Robinson, Melanie Schwerdtfeger, Virginia Tirino, Federica Papaccio, Michele Caraglia…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:20
  19. Colorectal carcinoma (CRC) is the third most common cancer and second most common cause of cancer-related deaths worldwide. Ribonucleic acid (RNA) N6-methyladnosine (m6A) and methyltransferase-like 3 (METTL3) ...

    Authors: Jiashu Pan, Feng Liu, Xiaoli Xiao, Ruohui Xu, Liang Dai, Mingzhe Zhu, Hanchen Xu, Yangxian Xu, Aiguang Zhao, Wenjun Zhou, Yanqi Dang and Guang Ji
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:19
  20. Neuronal-origin HuD (ELAVL4) is an RNA binding protein overexpressed in neuroblastoma (NB) and certain other cancers. The RNA targets of this RNA binding protein in neuroblastoma cells and their role in promot...

    Authors: Kausik Bishayee, Khadija Habib, Uddin Md. Nazim, Jieun Kang, Aniko Szabo, Sung-Oh Huh and Ali Sadra
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:18

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2022 41:52

  21. Dysregulation of RNA binding protein (RBP) expression has been confirmed to be causally linked with tumorigenesis. The detailed biological effect and underlying mechanisms of the RBP GRSF1 in hepatocellular ca...

    Authors: Lili Han, Chen Huang, Xiaofei Wang and Dongdong Tong
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:17

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2022 41:181

  22. KRAS is the predominant oncogene mutated in pancreatic ductal adenocarcinoma (PDAC), the fourth cause of cancer-related deaths worldwide. Mutant KRAS-driven tumors are metabolically programmed to support their...

    Authors: Maria Saliakoura, Matteo Rossi Sebastiano, Ioanna Nikdima, Chiara Pozzato and Georgia Konstantinidou
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:16
  23. Acquired resistance of 5-fluorouracil (5-FU) remains a clinical challenge in colorectal cancer (CRC), and efforts to develop targeted agents to reduce resistance have not yielded success. Metabolic reprogrammi...

    Authors: Shuohui Dong, Shuo Liang, Zhiqiang Cheng, Xiang Zhang, Li Luo, Linchuan Li, Wenjie Zhang, Songhan Li, Qian Xu, Mingwei Zhong, Jiankang Zhu, Guangyong Zhang and Sanyuan Hu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:15
  24. Chemoresistance is a main obstacle in gastric cancer (GC) treatment, but its molecular mechanism still needs to be elucidated. Here, we aim to reveal the underlying mechanisms of nanoparticle albumin-bound pac...

    Authors: Mengxuan Zhu, Pengfei Zhang, Shan Yu, Cheng Tang, Yan Wang, Zhenbin Shen, Weidong Chen, Tianshu Liu and Yuehong Cui
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:14
  25. Increasing evidence has suggested inositol polyphosphate 5-phosphatase family contributes to tumorigenesis and tumor progression. However, the role of INPP5F in hepatocellular carcinoma (HCC) and its underlyin...

    Authors: Qianlei Zhou, Jianhong Lin, Yongcong Yan, Shiyu Meng, Hao Liao, Ruibin Chen, Gui He, Yue Zhu, Chuanchao He, Kai Mao, Jie Wang, Jianlong Zhang, Zhenyu Zhou and Zhiyu Xiao
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:13
  26. The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is...

    Authors: Tal Flieswasser, Astrid Van den Eynde, Jonas Van Audenaerde, Jorrit De Waele, Filip Lardon, Carsten Riether, Hans de Haard, Evelien Smits, Patrick Pauwels and Julie Jacobs
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:12
  27. Currently, multiple myeloma (MM) is still an incurable plasma cell malignancy in urgent need of novel therapeutic targets and drugs.

    Authors: Chunyan Gu, Yajun Wang, Lulin Zhang, Li Qiao, Shanliang Sun, Miaomiao Shao, Xiaozhu Tang, Pinggang Ding, Chao Tang, Yuhao Cao, Yanyan Zhou, Mengjie Guo, Rongfang Wei, Nianguang Li, Yibei Xiao, Jinao Duan…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:11
  28. Tumor-associated macrophages (TAMs) have a leading position in the tumor microenvironment. Previously, we have demonstrated that M1-like TAMs activated by exosome-transferred THBS1 promote malignant migration ...

    Authors: Yuanhe You, Zhuowei Tian, Zhong Du, Kailiu Wu, Guisong Xu, Meilu Dai, Yan’an Wang and Meng Xiao
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:10
  29. Multiple myeloma (MM) is an incurable plasma cell malignancy. Although Dexamethasone (Dex) is the most widely used therapeutic drug in MM treatment, patients develop Dex resistance leading to progressive disea...

    Authors: Li Du, Wei Liu, Grace Aldana-Masangkay, Alex Pozhitkov, Flavia Pichiorri, Yuan Chen and Steven T. Rosen
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:8
  30. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Oxana Schmidt, Nadja Nehls, Carolin Prexler, Kristina von Heyking, Tanja Groll, Katharina Pardon, Heathcliff D. Garcia, Tim Hensel, Dennis Gürgen, Anton G. Henssen, Angelika Eggert, Katja Steiger, Stefan Burdach and Günther H. S. Richter
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:7

    The original article was published in Journal of Experimental & Clinical Cancer Research 2021 40:322

  31. Lymph node metastasis is the main cause of poor prognosis of head and neck squamous carcinoma (HNSCC) patients. N6-methyladenosine (m6A) RNA modification is an emerging epigenetic regulatory mechanism for gene...

    Authors: Dan Yu, Min Pan, Yanshi Li, Tao Lu, Zhihai Wang, Chuan Liu and Guohua Hu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:6
  32. Long non-coding RNAs (lncRNA) have an essential role in progression and chemoresistance of hepatocellular carcinoma (HCC). In-depth study of specific regulatory mechanisms is of great value in providing potent...

    Authors: Jie Mei, Wenping Lin, Shaohua Li, Yuhao Tang, Zhiwei Ye, Lianghe Lu, Yuhua Wen, Anna Kan, Jingwen Zou, Chengyou Yu, Wei Wei and Rongping Guo
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:5
  33. Therapeutic resistance occurs in most patients with multiple myeloma (MM). One of the key mechanisms for MM drug resistance comes from the interaction between MM cells and adipocytes that inhibits drug-induced...

    Authors: Zhiming Wang, Jin He, Duc-hiep Bach, Yung-hsing Huang, Zongwei Li, Huan Liu, Pei Lin and Jing Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:4
  34. Drug resistance to sorafenib greatly limited the benefits of treatment in patients with hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) participate in the development of drug resistance. The key miRNA regul...

    Authors: Yuanjun Lu, Yau-Tuen Chan, Hor-Yue Tan, Cheng Zhang, Wei Guo, Yu Xu, Rakesh Sharma, Zhe-Sheng Chen, Yi-Chao Zheng, Ning Wang and Yibin Feng
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:3
  35. B-cell maturation antigen (BCMA) chimeric antigen receptor T (CAR-T) cell therapy has obtained promising results in relapsed or refractory multiple myeloma (R/R MM), while some patients do not response, or rel...

    Authors: Yuanyan Tang, Haisen Yin, Xinying Zhao, Dan Jin, Yan Liang, Tao Xiong, Lu Li, Wen Tang, Jiangzhao Zhang, Min Liu, Zhuojun Yu, Huimin Liu, Sibin Zang and Zhiping Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:2
  36. Immune checkpoint inhibitor-related cardiotoxicity is one of the most lethal adverse effects, and thus, the identification of underlying mechanisms for developing strategies to overcome it has clinical importa...

    Authors: Yaxin Chen, Yanzhuo Liu, Yang Wang, Xuewei Chen, Chenlong Wang, Xuehan Chen, Xi Yuan, Lilong Liu, Jing Yang and Xiaoyang Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:1
  37. Authors: Jinxiao Li, Man Hu, Na Liu, Huarong Li, Zhaomin Yu, Qian Yan, Minfeng Zhou, Yayuan Wang, Yanjuan Song, Guangtao Pan, Fengxia Liang and Rui Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:404

    The original article was published in Journal of Experimental & Clinical Cancer Research 2020 39:248

  38. This article has been retracted. Please see the Retraction Notice for more detail: https://​doi.​org/​10.​1186/​s13046-021-02204-1

    Authors: Shan Zhou, Jinping Lu, Yuejin Li, Chan Chen, Yongqiang Cai, Gongjun Tan, Zhengke Peng, Zhenlin Zhang, Zigang Dong, Tiebang Kang and Faqing Tang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:401
  39. Authors: Jian Zhang, Xin Wen, Xian-Yue Ren, Ying-Qin Li, Xin-Ran Tang, Ya-Qin Wang, Qing-Mei He, Xiao-Jing Yang, Ying Sun, Na Liu and Jun Ma
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:400

    The original article was published in Journal of Experimental & Clinical Cancer Research 2016 35:109

  40. Most cancer cells have fundamentally different metabolic characteristics, particularly much higher glycolysis rates than normal tissues, which support the increased demand for biosynthesis and promote tumor pr...

    Authors: Yiwei Huang, Zhencong Chen, Tao Lu, Guoshu Bi, Ming Li, Jiaqi Liang, Zhengyang Hu, Yuansheng Zheng, Jiacheng Yin, Junjie Xi, Zongwu Lin, Cheng Zhan, Wei Jiang, Qun Wang and Lijie Tan
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:398
  41. Triple-negative breast cancer (TNBC) is the most heterogeneous and malignant subtype of breast cancer (BC). TNBC is defined by the absence of expression of estrogen, progesterone and HER2 receptors and lacks e...

    Authors: Chiara Naro, Monica De Musso, Francesca Delle Monache, Valentina Panzeri, Pierre de la Grange and Claudio Sette
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:397
  42. Authors: Xin Peng, Shaolu Zhang, Wenhui Jiao, Zhenxing Zhong, Yuqi Yang, Francois X. Claret, Moshe Elkabets, Feng Wang, Ran Wang, Yuxu Zhong, Zhe-Sheng Chen and Dexin Kong
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:396

    The original article was published in Journal of Experimental & Clinical Cancer Research 2021 40:374

  43. Breast cancer has been associated with activation of the WNT signaling pathway, although no driver mutations in WNT genes have been found yet. Instead, a high expression of the alternative WNT receptor ROR2 wa...

    Authors: Kerstin Menck, Saskia Heinrichs, Darius Wlochowitz, Maren Sitte, Helen Noeding, Andreas Janshoff, Hannes Treiber, Torben Ruhwedel, Bawarjan Schatlo, Christian von der Brelie, Stefan Wiemann, Tobias Pukrop, Tim Beißbarth, Claudia Binder and Annalen Bleckmann
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:395
  44. Authors: Jian Zhang, Xin Wen, Na Liu, Ying-Qin Li, Xin-Ran Tang, Ya-Qin Wang, Qing-Mei He, Xiao-Jing Yang, Pan-Pan Zhang, Jun Ma and Ying Sun
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:394

    The original article was published in Journal of Experimental & Clinical Cancer Research 2017 36:147

  45. Alterations in metabolism are one of the emerging hallmarks of cancer cells and targeting dysregulated cancer metabolism provides a new approach to developing more selective therapeutics. However, insufficient...

    Authors: Liwei Lang, Fang Wang, Zhichun Ding, Xiangdong Zhao, Reid Loveless, Jin Xie, Chloe Shay, Peng Qiu, Yonggang Ke, Nabil F. Saba and Yong Teng
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:393
  46. Flavonoids exhibit both chemopreventive and chemotherapeutic activity for multiple tumor types, however, their mechanisms of action are not well defined. Based on some of their functional and gene modifying ac...

    Authors: Rupesh Shrestha, Kumaravel Mohankumar, Greg Martin, Amanuel Hailemariam, Syng-ook Lee, Un-ho Jin, Robert Burghardt and Stephen Safe
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:392

Annual Journal Metrics